Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer

European Urology

Volumn 41, Issue 2, 2002, Pages 167-171

  Steiner, Thomas ^a   Junker, Kerstin ^a   Burkhardt, Frank ^a   Braunsdorf, Andreas ^a   Janitzky, Volker ^a   Schubert, Joerg ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

CGH; Hormone treatment; Prognosis; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CHROMOSOME 16Q; CHROMOSOME 17; CHROMOSOME 18Q; CHROMOSOME 6Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA ISOLATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 8; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HORMONES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STATISTICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036487691     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(01)00030-6     Document Type: Article

References (19)

1. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992;23:211-22.
2. Alers JC, Krijtenburg PJ, Hop WCM, Bolle WABM, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H. Longitudinal evaluation of cytogenetic aberrations in prostate cancer: Tumours that recur in time display an intermediate genetic status between nonpersistent and metastatic tumours. J Pathol 1998;185:273-83.
3. 0 prostate cancer. Genes Chromosomes Cancer 1998;21:131-43.
4. König JJ, Teubel W, van Dongen JW, Hagemeijer A, Romijn JC, Schröder FH. Tissue culture loss of aneuploid cells from carcinomas of the prostate. Genes Chromosomes Cancer 1993;8:22-7.
5. Brothman AR. Cytogenetic studies in prostate cancer: Are we making progress? Cancer Genet Cytogenet 1997;95:116-21.
6. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybidization for molecular cytogenetic analysis of solid tumors. Science 1992;258: 818-21.
7. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994;11:153-62.
8. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994;145:1301-8.
9. Visacorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comperative genomic hybridization. Cancer Res 1995;55:342-7.
10. Paiss T, Kemmerling R, Wysocka B, Mattfeld T, Vogel W, Kleinschmidt K, Hautmann R, Hameister H. 8p-Verluste in der CGH sind mit einem erhöhten Progreβrisiko beim organbegrenzten Prostatakarzinom assoziiert. Urologe [A] 1999;38(Suppl 1):93.
11. Chudoba I, Henn TK, Senger G, Claussen U, Haas OA. Comparative genomic hybridization using DOP-PCR amplified DNA from a small number of nuclei. Cs Pediat 1997;52:519-21.
12. Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, Tunnacliffe A. Degenerate oligonucleotide-primed PCR: General amplification of target DNA by a single degenerate primer. Genomics 1992;13:718-25.
13. Visakorpi T. Molecular genetics of prostate cancer. Ann Chir Gynaecol 1999;88:11-6.
14. Nupponen NN, Visakorpi T Molecular cytogenetics of prostate cancer. Microsc Res Tech 2000;51:456-63.
15. van den Berg C, Guan XY, von Hoff D, Jenkins R, Bittner M, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein J, Sarosdy M, Meltzer P, Trent J. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: Potential prognostic implications. Clin Cancer Res 1995;1:11-8.
16. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH, van Dekken H. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000;80:931-42.
17. Nupponen NN, Kakkola L, Kovisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
18. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WCJ, Verkerk AM, Schroeder FH, van der Kwast TH, Bosman FT, van Dekken H. Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 1997;77:437-48.
19. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van der Kwast TT, Schroeder FH, Tanke HJ, van Dekken H. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: Early cancers may contain aggressive genetic features. Am J Pathol 2001;158:399-406.